Drug Trial Radar · NCT05936359
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Sep 25, 2023
Primary completion
Feb 29, 2028
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Conditions
- Myeloproliferative Neoplasms
Interventions
INCA033989Drug
INCA033989 will be administered at protocol defined dose.
RuxolitinibDrug
Rux will be administered according to Prescribing Information/SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years and 60 days
- Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to 3 years and 60 days
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
Royal Brisbane and Women'S Hospital
Herston, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Hopital Maisonneuve-Rosemont, Montreal, Qc
Montreal, Quebec, Canada
Sjaellands Universitetshospital
Roskilde, Denmark
Vejle Hospital
Vejle, Denmark
Institut Bergonie
Bordeaux, France
Chu Nimes
Nîmes, France
Hospital Saint Louis
Paris, France
Institut Gustave Roussy
Villejuif, France
University Medical Center Rwth Aachen
Aachen, Germany
Universitatsklinikum Halle (Saale)
Halle, Germany
Universitätsklinikum Ulm
Ulm, Germany
Aou Policlinico S. Orsola-Malpighi
Bologna, Italy
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, Italy
Fondazione Irccs Ca Granda Ospedale Maggiore
Milan, Italy
National Cancer Center Hospital East
Chiba-ken, Japan
Kagoshima University Hospital
Kagoshima, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Nippon Medical School Hospital
Tokyo, Japan
Mie University Hospital
Tsu, Japan
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitari I Politecnic La Fe
Valencia, Spain
Guys and St Thomas Nhs Foundation Trust
London, United Kingdom
The Christie Nhs Foundation Trust Uk
Manchester, United Kingdom
University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.